Bayer AG (XETR:BAYN) has created Ruveon LLC to centralize U.S. glyphosate operations under new leadership while simultaneously reviewing strategic options after missing a Medicaid MFN pilot deadline; the moves sparked up to a 7.1% jump in shares and an analyst upgrade.
Previous Week Recap
- Bayer Centralizes U.S. Glyphosate Operations: Bayer created Ruveon LLC in St. Louis to centralize U.S. glyphosate (including Roundup) pricing, production, logistics and sales; Alfonso Alba Ordóñez named CEO, Steve Knodle heads U.S. commercial.
- Bayer Shares Jump On Upgrade: Bayer shares rose as much as 7.1% after an announcement, with Deutsche Bank upgrading the stock and citing the potential near-term breakup of Bayer’s portfolio.
- Bayer Reviews U.S. Pricing Options: Bayer (BAYN) is reviewing options after missing the U.S. Medicaid MFN pricing pilot application deadline; company assessing potential impacts on U.S. drug pricing and access.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.